Multi-event July 2023 FDA Recall Drug by Central Admixture Pharmacy Services Inc

This Multi-event Class II drug recall was voluntarily initiated by Central Admixture Pharmacy Services Inc on July 17, 2023 for the product Drug. The FDA reported the reason for recall as lack of assurance of sterility. The product was distributed Nationwide and the recall is currently terminated.

Reported Recall Events

D-1068-2023 TERMINATED D-1064-2023 TERMINATED D-1048-2023 TERMINATED D-1073-2023 TERMINATED D-1052-2023 TERMINATED D-1067-2023 TERMINATED D-1055-2023 TERMINATED D-1072-2023 TERMINATED D-1057-2023 TERMINATED D-1044-2023 TERMINATED D-1053-2023 TERMINATED D-1054-2023 TERMINATED D-1058-2023 TERMINATED D-1075-2023 TERMINATED D-1050-2023 TERMINATED D-1069-2023 TERMINATED D-1059-2023 TERMINATED D-1065-2023 TERMINATED D-1045-2023 TERMINATED D-1063-2023 TERMINATED D-1070-2023 TERMINATED D-1078-2023 TERMINATED D-1071-2023 TERMINATED D-1051-2023 TERMINATED D-1079-2023 TERMINATED D-1056-2023 TERMINATED D-1060-2023 TERMINATED D-1080-2023 TERMINATED D-1046-2023 TERMINATED D-1042-2023 TERMINATED D-1062-2023 TERMINATED D-1049-2023 TERMINATED D-1076-2023 TERMINATED D-1047-2023 TERMINATED D-1043-2023 TERMINATED D-1077-2023 TERMINATED D-1066-2023 TERMINATED D-1061-2023 TERMINATED D-1074-2023 TERMINATED

Recall Number: D-1068-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
723 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
morphine in 0.9% sodium chloride, 125 mg/25 mL, (5 mg/mL), 30 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2041-2

Batch or Lot Expiration Information

Lot# Lot: 17-271060, Exp. 7/24/2023; 17-271252, Exp. 7/26/2023; 17-271571, Exp. 8/1/2023; 17-272471, Exp. 8/16/2023; 17-272785, Exp. 8/22/2023.

Recall Number: D-1064-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
1,699 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
morphine in 0.9% sodium chloride, 1 mg/1 mL, (1 mg/mL), 3 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2040-1

Batch or Lot Expiration Information

Lot# Lot: 17-270804, Exp. 7/19/2023; 17-271108, Exp. 7/25/2023; 17-271496, Exp. 7/31/2023; 17-271844, Exp. 8/6/2023; 17-272045, Exp. 8/9/2023; 17-272288, Exp. 8/14/2023.

Recall Number: D-1048-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
2,640 Syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
vecuronium, 10 mg/10mL, (1 mg/mL), 10 mL syringe, Rx only, PARALYZING AGENT, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6012-1.

Batch or Lot Expiration Information

Lot# Lot: 17-273867, Exp.9/10/2023; 17-272606, Exp.8/20/2023; 17-272225, 8/13/2023; 17-272036, Exp. 8/9/2023; 17-271503, Exp. 7/31/2023; 17-271427, Exp. 7/30/2023; 17-271264, Exp. 7/26/2023; 17-270970, Exp.7/23/2023; 17-270784, Exp. 7/19/2023; 17-270674, Exp. 7/18/2023.

Recall Number: D-1073-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
8,942 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
ePHEDrine in 0.9% sodium chloride, 50 mg /5 mL, (10 mg/mL), 5 mL Syringe, Rx only, CAPS Inc., Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6004-1

Batch or Lot Expiration Information

Lot# Lot: 17-270545, Exp. 7/16/2023; 17-270614, Exp. 7/17/2023; 17-270885, 17-270897, Exp. 7/20/2023; 17-270980, 17-270992, Exp. 7/23/2023; 17-271268, Exp. 7/26/2023; 17-271338, Exp. 7/27/2023; 17-271426, 17-271428, Exp. 7/30/2023; 17-271691, Exp. 8/2/2023; 17-271843, Exp. 8/6/2023; 17-271963, Exp. 8/8/2023; 17-272136, Exp. 8/10/2023; 17-272215, Exp. 8/13/2023; 17-272304, Exp. 8/14/2023; 17-272379, Exp. 8/15/2023; 17-272462, Exp. 8/16/2023; 17-272641, Exp. 8/20/2023; 17-272698, Exp. 8/21/2023; 17-273602, 17-273627, Exp. 9/5/2023; 17-273883, Exp. 9/10/2023.

Recall Number: D-1052-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
3824 bags

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
HYDROmorphone added to 0.9% sodium chloride, 10 mg/50 mL, (0.2 mg/mL), 100 mL bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2010-3

Batch or Lot Expiration Information

Lot# Lot: 17-270599, 17-270600, Exp. 7/17/2023; 17-270785, Exp. 7/19/2023; 17-270969, Exp. 7/23/2023; 17-271116, 17-271135, Exp. 7/25/2023; 17-271242, Exp. 7/26/2023; 17-271502, Exp. 7/31/2023; 17-271561, 17-271589, Exp. 8/1/2023; 17-271672, Exp. 8/2/2023; 17-271837, Exp. 8/6/2023; 17-272291, Exp. 8/14/2023; 17-272363, 17-272364, Exp. 8/15/2023; 17-272453, Exp. 8/16/2023; 17-272607, Exp. 8/20/2023; 17-272706, Exp. 8/21/2023; 17-273148, Exp. 8/29/2023; 17-273421, Exp. 9/3/2023; 17-273698, 17-273700, Exp. 9/6/2023; 17-273966, Exp. 9/11/2023.

Recall Number: D-1067-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
1,486 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL 1.5 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chloride, Total Volume = 50 mL, Total fentaNYL 75 mcg/50 mL, 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2080-2

Batch or Lot Expiration Information

Lot# Lot: 17-270811, Exp. 7/19/2023; 17-270954, 17-270983, Exp. 7/23/2023; 17-271231, Exp. 7/26/2023; 17-271690, Exp. 8/2/2023; 17-272204, Exp. 8/13/2023; 17-272684, Exp. 8/20/2023; 17-272992, Exp. 8/24/2023; 17-273053, Exp. 8/28/2023; 17-273436, Exp. 9/3/2023.

Recall Number: D-1055-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
2,389 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
HYDROmorphone in 0.9% sodium chloride, 10 mg/50 mL, (0.2 mg/mL), 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2010-2

Batch or Lot Expiration Information

Lot# Lot: 17-270530, Exp. 7/16/2023; 17-270871, Exp. 7/20/2023; 17-271153, Exp. 7/25/2023; 17-271275, Exp. 7/26/2023; 17-271417, Exp. 7/30/2023; 17-271671, Exp. 8/2/2023; 17-271883, Exp. 8/7/2023; 17-271992, Exp. 8/8/2023; 17-272050, Exp. 8/9/2023; 17-272103, Exp. 8/10/2023; 17-272368, 17-272369, Exp. 8/15/2023; 17-272451, Exp. 8/16/2023; 17-273172, Exp. 8/29/2023; 17-273782, Exp. 9/7/2023.

Recall Number: D-1072-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
896 bags

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL 2 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chloride / Total Volume = 250 mL, Total fentaNYL 500 mcg/250 mL, bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2082-2

Batch or Lot Expiration Information

Lot# Lot: 17-270540, Exp. 7/16/2023; 17-270663, Exp. 7/18/2023; 17-271059, Exp. 7/24/2023; 17-271249, Exp. 7/26/2023; 17-271593, Exp. 8/1/2023; 17-271742, Exp. 8/3/2023; 17-272064, Exp. 8/9/2023; 17-272106, Exp. 8/10/2023; 17-272279, Exp. 8/14/2023; 17-272530, Exp. 8/17/2023; 17-272603, Exp. 8/20/2023; 17-272776, Exp. 8/22/2023; 17-273075, Exp. 8/28/2023; 17-273344, Exp. 8/31/2023; 17-273409, Exp. 9/3/2023; 17-274221, 17-274222, Exp. 9/14/2023; 17-274414, Exp. 9/18/2023.

Recall Number: D-1057-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
1,389 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
HYDROmorphone in Dextrose 5%, 0.5 mg/5 mL (0.1 mg/mL), 5 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2013-1

Batch or Lot Expiration Information

Lot# Lot: 17-270683, Exp 7/18/2023; 17-271119, Exp 7/25/2023; 17-271339, Exp 7/27/2023; 17-272202, Exp 8/10/2023; 17-272241, Exp 8/13/2023; 17-272783, Exp 8/22/2023; 17-273431, Exp 9/3/2023; 17-273615, Exp 9/5/2023

Recall Number: D-1044-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
2,717 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
HYDROmorphone in 0.9% sodium chloride, 6 mg/30 mL, (0.2 mg/mL), 30 mL Syringe, Rx only, CAPS, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2010-1

Batch or Lot Expiration Information

Lot# Lot: 17-270603, Exp. 7/17/2023; 17-270802, Exp. 7/19/2023; 17-271073, Exp. 7/24/2023; 17-271129, Exp. 7/25/2023; 17-271254, Exp. 7/26/2023; 17-271953, Exp. 8/8/2023; 17-272022, Exp. 8/9/2023; 17-272295, Exp. 8/14/2023; 17-272616, Exp. 8/20/2023; 17-273357, Exp. 8/31/2023; 17-273501, Exp. 9/4/2023.

Recall Number: D-1053-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
1669 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL in 0.9% sodium chloride, 100 mcg/10 mL, (10 mcg/mL), 10 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2071-2

Batch or Lot Expiration Information

Lot# Lot: 17-270685, Exp. 7/18/2023; 17-271343, Exp. 7/27/2023; 17-271490, Exp. 7/31/2023; 17-271578, Exp. 8/1/2023; 17-272293, Exp. 8/14/2023; 17-272786, Exp. 8/22/2023; 17-273575, Exp. 9/5/2023.

Recall Number: D-1054-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
2,082 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL in 0.9% sodium chloride, 500 mcg/50 mL, (10 mcg/mL), 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2071-3

Batch or Lot Expiration Information

Lot# Lot: 17-271133, 17-271155, Exp. 7/25/2023; 17-271568, 17-271569, Exp. 8/1/2023; 17-271741, 17-271762, Exp. 8/3/2023; 17-272051, Exp. 8/9/2023; 17-272227, Exp. 8/13/2023; 17-272343, Exp. 8/15/2023; 17-272799, Exp. 8/22/2023; 17-273173, Exp. 8/29/2023; 17-273495, Exp. 9/4/2023.

Recall Number: D-1058-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
2,077 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
HYDROmorphone in 0.9% sodium chloride, 15 mg/30 mL, (0.5 mg/mL), 30 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2011-1

Batch or Lot Expiration Information

Lot# Lot: 17-270770, Exp. 7/19/2023; 17-271061, Exp. 7/24/2023; 17-271419, Exp. 7/30/2023; 17-271678, Exp. 8/2/2023; 17-272124, Exp. 8/10/2023; 17-272302, Exp. 8/14/2023; 17-272518, Exp. 8/17/2023; 17-273493, Exp. 9/4/2023; 17-273671, Exp. 9/6/2023.

Recall Number: D-1075-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
621 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
midazolam in dextrose 5%, 50 mg /50 mL, (1 mg/mL), 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-4036-1

Batch or Lot Expiration Information

Lot# Lot: 17-270666, Exp. 7/18/2023; 17-270879, Exp. 7/20/2023; 17-271669, Exp. 8/2/2023; 17-272287, Exp. 8/14/2023; 17-272366, Exp. 8/15/2023; 17-272991, Exp. 8/24/2023; 17-273512, Exp. 9/4/2023.

Recall Number: D-1050-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
848 bags

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL, 2500 mcg/50 mL, (50 mcg/mL), 100 mL bag, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2003-4

Batch or Lot Expiration Information

Lot# Lot: 17-270533, Exp. 7/16/2023; 17-270580, 17-270581, Exp. 7/17/2023; 17-270654, Exp. 7/18/2023; 17-271044, Exp. 7/24/2023; 17-271243, Exp. 7/26/2023; 17-271439, Exp. 7/30/2023; 17-271562, Exp. 8/1/2023.

Recall Number: D-1069-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
295 bags

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL 2 mcg/mL and bupivacaine 0.0625% PF in 0.9% sodium chloride, Total Volume = 250 mL, Total fentaNYL 500 mcg/250 mL, 250 mL bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2081-1

Batch or Lot Expiration Information

Lot# Lot: 17-271814, Exp. 8/6/2023; 17-271960, Exp. 8/8/2023; 17-272252, Exp. 8/13/2023; 17-272272, Exp. 8/14/2023; 17-272454, Exp. 8/16/2023; 17-272640, Exp. 8/20/2023; 17-272716, Exp. 8/21/2023.

Recall Number: D-1059-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
19,014 bags

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL in 0.9% sodium chloride, 1000 mcg/100 mL, (10 mcg/mL), 100 mL bag, Rx only, CAPS, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2071-4

Batch or Lot Expiration Information

Lot# Lot: 17-270499, 17-270500, 17-270503, 17-270511, 17-270518, 17-270544, Exp. 7/16/2023; 17-270778, 17-270779, Exp. 7/19/2023; 17-270957, 17-270958, 17-270959, 17-270965, 17-270972, 17-270982, 17-270984, 17-270985, Exp. 7/23/2023; 17-271043, Exp. 7/24/2023; 17-271232, 17-271240, 17-271266, Exp. 7/26/2023; 17-271326, 17-271327, 17-271328, 17-271329, 17-271341, 17-271342, Exp. 7/27/2023; 17-271399, 17-271400, 17-271401, Exp. 7/30/2023; 17-271481, 17-271482, 17-271483, 17-271488, 17-271489, 17-271491, 17-271510, Exp. 7/31/2023; 17-271590, 17-271661, Exp. 8/1/2023; 17-271655, 17-271656, 17-271668, 17-271675, 17-271677, Exp. 8/2/2023; 17-271759, Exp. 8/3/2023; 17-271825, Exp. 8/6/2023; 17-271880, 17-271881, 17-271885, Exp. 8/7/2023; 17-271939, 17-271941, 17-271942, 17-271952, 17-271961, Exp. 8/8/2023; 17-272017, 17-272018, 17-272066, Exp. 8/9/2023; 17-272107, Exp. 8/10/2023; 17-272211, Exp. 8/13/2023; 17-272354, 17-272356, 17-272365, 17-272376, 17-272380, Exp. 8/15/2023; 17-272448, 17-272450, 17-272455, 17-272467, 17-272468, Exp. 8/16/2023; 17-272532, 17-272537, 17-272548, 17-272550, Exp. 8/17/2023; 17-272597, 17-272598, 17-272602, 17-272624, 17-272644, 17-272652, Exp. 8/20/2023; 17-273020, Exp. 8/27/2023; 17-273062, 17-273066, 17-273067, Exp. 8/28/2023; 17-273234, 17-273239, 17-273240, 17-273241, 17-273243, 17-273244, Exp. 8/30/2023; 17-273410, 17-273419, 17-273420, 17-273422, 17-273435, 17-273439, Exp. 9/3/2023; 17-273609, Exp. 9/5/2023; 17-273673, 17-273701, 17-273727, Exp. 9/6/2023; 17-273860, 17-273863, 17-273864, 17-273868, Exp. 9/10/2023; 17-273976, Exp. 9/11/2023; 17-274051, Exp. 9/12/2023.

Recall Number: D-1065-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
720 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
morphine in 0.9% sodium chloride, 30 mg/30 mL, (1 mg/mL), 30 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2040-3

Batch or Lot Expiration Information

Lot# Lot: 17-270814, Exp. 7/19/2023; 17-271253, Exp. 7/26/2023; 17-271336, Exp. 7/27/2023; 17-271689, Exp. 8/2/2023.

Recall Number: D-1045-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
150 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL, 100 mcg/2 mL, (50 mcg/mL), 3 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2003-1

Batch or Lot Expiration Information

Lot# Lot: 17-272549, Exp. 8/15/2023; 17-273342, Exp. 8/31/2023; 17-274076, Exp. 9/13/2023.

Recall Number: D-1063-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
1,044 bags

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL in 0.9% sodium chloride, 5000 mcg/250 mL, (20 mcg/mL), 250 mL Bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2074-1

Batch or Lot Expiration Information

Lot# Lot: 17-271115, Exp. 7/25/2023; 17-271398, Exp. 7/30/2023; 17-272278, Exp. 8/14/2023; 17-272449, Exp. 8/16/2023; 17-272521, Exp. 8/17/2023; 17-272900, Exp. 8/23/2023; 17-273146, Exp. 8/29/2023; 17-273236, Exp. 8/30/2023; 17-273404, Exp. 9/3/2023; 17-273678, Exp. 9/6/2023; 17-273954, Exp. 9/11/2023; 17-274213, Exp. 9/14/2023.

Recall Number: D-1070-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
1,114 bags

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL 2 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chloride, Total Volume = 100 mL, Total FentaNYL 200 mcg/100 mL, 100 mL bag, Rx only, CAPS, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2082-1

Batch or Lot Expiration Information

Lot# Lot: 17-274485, Exp. 9/19/2023; 17-270783, Exp. 7/19/2023; 17-270882, Exp. 7/20/2023; 17-271430, Exp. 7/30/2023; 17-271509, Exp. 7/31/2023; 17-272224, 17-272238, Exp. 8/13/2023; 17-272704, Exp. 8/21/2023; 17-273147, Exp. 8/29/2023.

Recall Number: D-1078-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
16,971 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
PHENYLephrine in 0.9 sodium chloride, 400 mcg /10 mL, (40 mcg/mL), 10 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6007-1

Batch or Lot Expiration Information

Lot# Lot: 17-270510, 17-270512, Exp. 7/16/2023; 17-270665, 17-270699, Exp. 7/18/2023; 17-270812, Exp. 7/19/2023; 17-271062, 17-271063, 17-271064, 17-271065, Exp. 7/24/2023; 17-271350, 17-271357, 17-271421, 17-271422, Exp. 7/30/2023; 17-271836, 17-271848, Exp. 8/6/2023; 17-271890, Exp. 8/7/2023; 17-271943, 17-271954, 17-271958, 17-271962, Exp. 8/8/2023; 17-272162, 17-272174, 17-272175, 17-272176, 17-272177, Exp. 8/13/2023; 17-272444, 17-272456, 17-272473, Exp. 8/16/2023; 17-272717, 17-272721, 17-272732, Exp. 8/21/2023; 17-273550, 17-273565, 17-273579, 17-273580, Exp. 9/5/2023.

Recall Number: D-1071-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
2,994 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
ketamine in 0.9% sodium chloride, 50 mg/5mL (10mg/mL), 5 mL syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-3022-1

Batch or Lot Expiration Information

Lot# Lot: 17-274122, 17-274147, 17-274155, 17-274158, 17-274162, Exp. 9/13/2023

Recall Number: D-1051-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
94 bags

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL, 5000 mcg/100 mL, (50 mcg/mL), 100 mL Bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2003-5

Batch or Lot Expiration Information

Lot# Lot: 17-273074, Exp. 8/28/2023; 17-273772, Exp. 9/7/2023.

Recall Number: D-1079-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
6,770 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL in 0.9% sodium chloride, 10 mcg/1 mL, (10 mcg/mL), 3 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C San Diego, CA 92126, NDC: 71286-2071-1

Batch or Lot Expiration Information

Lot# Lot: 17-270539, Exp. 7/16/2023; 17-270981, Exp. 7/23/2023; 17-271167, Exp. 7/25/2023; 17-271337, Exp. 7/27/2023; 17-271827, Exp. 8/6/2023; 17-272214, Exp. 8/13/2023; 17-272536, 17-272555, Exp. 8/17/2023; 17-273424, 17-273432, Exp. 9/3/2023; 17-273476, Exp. 9/4/2023; 17-273882, Exp. 9/10/2023; 17-274044, Exp. 9/12/2023.

Recall Number: D-1056-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
12,239 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
succinylcholine, 200 mg/10 mL, (20 mg/mL), 10 mL syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6011-2

Batch or Lot Expiration Information

Lot# Lot: 17-270532, 17-270538, Exp, 7/16/2023; 17-270601, Exp, 7/17/2023; 17-270888, Exp, 7/20/2023; 17-271680, Exp, 8/2/2023; 17-271828, Exp, 8/6/2023; 17-271959, Exp, 8/8/2023; 17-272232, 17-272239, Exp, 8/13/2023; 17-272338, Exp, 8/15/2023; 17-272452, 17-272463, Exp, 8/16/2023; 17-272551, 17-272557, Exp, 8/17/2023; 17-272800, 17-272819, Exp, 8/22/2023; 17-272889, 17-272917, Exp, 8/23/2023; 17-272978, Exp, 8/24/2023; 17-273077, Exp, 8/28/2023; 17-273166, Exp, 8/29/2023; 17-273604, Exp, 9/5/2023; 17-273729, 17-273731, Exp, 9/6/2023; 17-273854, 17-273870, Exp, 9/10/2023

Recall Number: D-1060-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
5,259 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
HYDROmorphone in 0.9% sodium chloride, 30 mg/30 mL, (1 mg/mL), 30 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2012-1

Batch or Lot Expiration Information

Lot# Lot: 17-270534, Exp. 7/16/2023; 17-270705, Exp. 7/18/2023; 17-270782, 17-270797, 17-270798, Exp. 7/19/2023; 17-270968, Exp. 7/23/2023; 17-271105, 17-271154, Exp. 7/25/2023; 17-271251, Exp. 7/26/2023; 17-271330, Exp. 7/27/2023; 17-271418, Exp. 7/30/2023; 17-271746, 17-271758, Exp. 8/3/2023; 17-272108, Exp. 8/10/2023; 17-272257, Exp. 8/13/2023; 17-272344, 17-272355, Exp. 8/15/2023; 17-272442, Exp. 8/16/2023; 17-272801, Exp. 8/22/2023; 17-273511, Exp. 9/4/2023; 17-273576, 17-273611, Exp. 9/5/2023; 17-274048, 17-274050, Exp. 9/12/2023.

Recall Number: D-1080-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
1,235 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
morphine in 0.9% Sodium Chloride, 50 mg/50 mL (1mg/mL), 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C San Diego, CA 92126, NDC: 71286-2040-4

Batch or Lot Expiration Information

Lot# Lot: 17-273353, Exp 8/31/2023, 17-270602, Exp 7/17/2023; 17-270706, Exp 7/18/2023; 17-271416, Exp 7/30/2023; 17-272049, Exp 8/9/2023; 17-272277, Exp 8/14/2023; 17-273231, Exp 8/30/2023.

Recall Number: D-1046-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
100 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL, 250 mcg/5 mL, (50 mcg/mL), 5 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2003-2

Batch or Lot Expiration Information

Lot# Lot: 17-273267, Exp. 8/31/2023.

Recall Number: D-1042-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
1,197 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL in dextrose 5%, 300 mcg/30 mL, (10 mcg/mL), 30 mL syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C San Diego, CA 92126, NDC: 71286-2001-2

Batch or Lot Expiration Information

Lot# Lot: 17-271144, Exp. 7/25/2023; 17-271354, Exp. 7/27/2023; 17-271681, Exp. 8/2/2023; 17-271990, Exp. 8/7/2023; 17-272457, Exp. 8/16/2023.

Recall Number: D-1062-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
2,340 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL in 0.9% sodium chloride, 10 mcg/1 mL, (10 mcg/mL), 3 mL syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2071-7

Batch or Lot Expiration Information

Lot# Lot: 17-270813, Exp. 7/19/2023; 17-271485, Exp. 7/31/2023; 17-271809, Exp. 8/6/2023; 17-272314, Exp. 8/14/2023; 17-272780, Exp. 8/22/2023; 17-273141, Exp. 8/29/2023; 17-273687, Exp. 9/6/2023.

Recall Number: D-1049-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
2,228 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
HYDROmorphone in dextrose 5%, 3 mg/30 mL, (0.1 mg/mL), 30 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2013-2

Batch or Lot Expiration Information

Lot# Lot: 17-270675, 17-270683, Exp. 7/18/2023; 17-271147, 17-271119, Exp. 7/25/2023; 17-271339, Exp. 7/27/2023; 17-271679, Exp. 8/2/2023; 17-272202, Exp. 8/10/2023; 17-272241, Exp. 8/13/2023; 17-272375, Exp. 8/15/2023; 17-272783, Exp. 8/22/2023; 17-273438, 17-273431, Exp. 9/3/2023; 17-273615, Exp. 9/5/2023; 17-273789, 9/7/2023.

Recall Number: D-1076-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
10,065 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
rocuronium, 50 mg /5 mL, (10 mg/mL), 5 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6010-1

Batch or Lot Expiration Information

Lot# Lot: 17-270519, Exp. 7/16/2023; 17-270605, Exp. 7/17/2023; 17-270684, Exp. 7/18/2023; 17-270898, Exp. 7/20/2023; 17-271074, Exp. 7/24/2023; 17-271324, Exp. 7/27/2023; 17-271603, Exp. 8/1/2023; 17-271670, Exp. 8/2/2023; 17-272529, Exp. 8/17/2023; 17-272883, Exp. 8/23/2023; 17-273235, 17-273245, 17-273262, 17-273263, 17-273264, Exp. 8/30/2023; 17-273418, Exp. 9/3/2023; 17-273768, 17-273788, Exp. 9/7/2023; 17-274022, Exp. 9/12/2023.

Recall Number: D-1047-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
1,216 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL, 2500 mcg/50 mL, (50 mcg/mL), 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2003-3

Batch or Lot Expiration Information

Lot# Lot: 17-270771, Exp. 7/19/2023; 17-271134, Exp. 7/25/2023; 17-271577, Exp. 8/1/2023; 17-271745, Exp. 8/3/2023; 17-272026, Exp. 8/9/2023; 17-272345, Exp. 8/15/2023; 17-272615, Exp. 8/20/2023; 17-273668, Exp. 9/6/2023.

Recall Number: D-1043-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
5,124 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL, 1250 mcg/25 mL, (50 mcg/mL), 30 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2003-7

Batch or Lot Expiration Information

Lot# Lot: 17-270664, Exp. 7/18/2023; 17-270886, Exp. 7/20/2023; 17-270976, 17-270989, Exp. 7/23/2023; 17-271335, Exp. 7/27/2023; 17-271572, Exp. 8/1/2023; 17-271747, Exp. 8/3/2023; 17-271808, Exp. 8/6/2023; 17-272023, Exp. 8/9/2023; 17-272203, Exp. 8/13/2023; 17-272718, Exp. 8/21/2023; 17-272797, Exp. 8/22/2023; 17-273157, Exp. 8/29/2023; 17-273507, Exp. 9/4/2023; 17-273766, Exp. 9/7/2023; 17-273862, Exp. 9/10/2023; 17-274052, Exp. 9/12/2023; 17-274208, Exp. 9/14/2023.

Recall Number: D-1077-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
10,494 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
PHENYLephrine in 0.9 sodium chloride, 800 mcg /10 mL, (80 mcg/mL), 10 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6008-1

Batch or Lot Expiration Information

Lot# Lot: 17-270678, 17-270695, Exp. 7/18/2023; 17-270880, Exp. 7/20/2023; 17-271075, Exp. 7/24/2023; 17-271233, 17-271269, Exp. 7/26/2023; 17-271492, 17-271494, Exp. 7/31/2023; 17-271748, Exp. 8/3/2023; 17-271891, Exp. 8/7/2023; 17-271945, Exp. 8/8/2023; 17-272221, 17-272236, Exp. 8/13/2023; 17-272286, 17-272305, Exp. 8/14/2023; 17-272642, Exp. 8/20/2023; 17-272997, 17-272998, Exp. 8/24/2023; 17-273478, 17-273496, 17-273497, Exp. 9/4/2023; 17-274139, 17-274156, 17-274163, Exp. 9/13/2023.

Recall Number: D-1066-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
81,073 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
PHENYLephrine in 0.9% sodium chloride, 1000 mcg/10 mL, (100 mcg/mL), 10 mL syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6009-1

Batch or Lot Expiration Information

Lot# Lot: 17-270449, 17-270450, 17-270453, 17-270462, 17-270465, 17-270466, 17-270494, 17-270495, 17-270502, 17-270541, Exp. 7/16/2023; 17-270582, 17-270585, 17-270587, 17-270592, 17-270593, 17-270598, 17-270610, 17-270611, 17-270612, Exp. 7/17/2023; 17-270900, 17-270902, 17-270906, 17-270907, 17-270908, 17-270909, 17-270953, 17-270955, 17-270991, 17-270993, Exp. 7/23/2023; 17-271047, 17-271048, 17-271050, 17-271053, Exp. 7/24/2023; 17-271344, 17-271349, 17-271355, 17-271356, 17-271405, 17-271406, Exp. 7/31/2023; 17-271478, 17-271479, 17-271480, 17-271484, 17-271495, 17-271500, Exp. 7/31/2023; 17-271744, 17-271763, Exp. 8/3/2023; 17-271838, 17-271851, Exp. 8/6/2023; 17-271871, 17-271873, 17-271886, 17-271887, 17-271892, 17-271899, 17-271900, 17-271901, 17-271902, Exp. 8/7/2023; 17-272067, 17-272068, 17-272069, 17-272095, Exp. 8/9/2023; 17-272102, 17-272141, 17-272142, Exp. 8/10/2023; 17-272205, 17-272235, 17-272237, 17-272240, 17-272242, Exp. 8/13/2023; 17-272307, 17-272308, Exp. 8/14/2023; 17-272391, 17-272392, 17-272395, Exp. 8/15/2023; 17-272472, Exp. 8/16/2023; 17-272538, Exp. 8/17/2023; 17-272558, 17-272560, 17-272564, 17-272593, 17-272594, 17-272618, 17-272619, 17-272651, 17-272653, 17-272680, Exp. 8/20/2023; 17-272697, 17-272727, 17-272729, Exp. 8/21/2023; 17-272775, 17-272791, 17-272820, 17-272821, Exp. 8/22/2023; 17-272904, 17-272918, 17-272919, 17-272920, 17-272921, 17-272929, Exp. 8/23/2023; 17-272930, 17-272974, 17-272993, 17-272994, 17-272995, 17-272996, Exp. 8/24/2023; 17-272999, 17-273003, 17-273004, 17-273005, 17-273006, 17-273007, Exp. 8/27/2023; 17-273080, Exp. 8/28/2023; 17-273151, 17-273175, 17-273176, 17-273185, Exp. 8/29/2023; 17-273252, 17-273265, 17-273266, Exp. 8/30/2023; 17-273345, 17-273351, 17-273352, 17-273355, 17-273356, 17-273358, 17-273359, 17-273360, Exp. 8/31/2023; 17-273402, 17-273408, 17-273416, 17-273440, 17-273441, 17-273447, Exp. 9/3/2023; 17-273487, 17-273488, 17-273489, 17-273490, 17-273491, 17-273499, 17-273510, 17-273516, Exp. 9/4/2023; 17-273587, 17-273589, 17-273596, 17-273597, 17-273610, 17-273614, 17-273666, Exp. 9/5/2023; 17-273617, 17-273665, 17-273703, 17-273704, 17-273713, 17-273714, 17-273720, 17-273721, 17-273730, 17-273737, 17-273739, Exp. 9/6/2023; 17-273773, Exp. 9/7/2023; 17-273802, 17-273803, 17-273808, 17-273809, 17-273815, 17-273848, 17-273869, 17-273874, 17-273880, 17-273881, 17-273893, Exp. 9/10/2023; 17-273903, 17-273958, 17-273960, 17-273961, 17-273964, 17-273965, Exp. 9/11/2023.

Recall Number: D-1061-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
8,146 bags

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
fentaNYL in 0.9% sodium chloride, 2500 mcg/250 mL, (10 mcg/mL), 250 mL bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2071-5

Batch or Lot Expiration Information

Lot# Lot: 17-270584, 17-270586, 17-270597, 17-270613, Exp. 7/17/2023; 17-270655, 17-270659, 17-270741, Exp. 7/18/2023; 17-270872, 17-270875, Exp. 7/20/2023; 17-271040, 17-271041, 17-271042, 17-271058, 17-271066, 17-271071, 17-271080, Exp. 7/24/2023; 17-271111, 17-271148, 17-271150, 17-271151, 17-271152, 17-271166, Exp. 7/25/2023; 17-271241, 17-271267, Exp. 7/26/2023; 17-271402, 17-271407, 17-271413, 17-271429, Exp. 7/30/2023; 17-271555, 17-271556, 17-271560, 17-271594, Exp. 8/1/2023; 17-271754, Exp. 8/3/2023; 17-271797, 17-271799, 17-271821, 17-271842, Exp. 8/6/2023; 17-271888, 17-271889, Exp. 8/7/2023; 17-271949, 17-271950, Exp. 8/8/2023; 17-272021, 17-272041, Exp. 8/9/2023; 17-272285, 17-272292, 17-272309, 17-272316, Exp. 8/14/2023; 17-272705, 17-272708, 17-272709, 17-272722, 17-272725, Exp. 8/21/2023; 17-272784, 17-272810, Exp. 8/22/2023; 17-272916, Exp. 8/23/2023; 17-272981, 17-272982, 17-272983, 17-272984, Exp. 8/24/2023; 17-273144, 17-273145, 17-273158, 17-273159, 17-273165, Exp. 8/29/2023; 17-273480, 17-273485, 17-273492, 17-273494, 17-273498, Exp. 9/4/2023; 17-273567, 17-273568, 17-273578, 17-273603, Exp. 9/5/2023; 17-273767, 17-273777, 17-273781, Exp. 9/7/2023; 17-273980, Exp. 9/11/2023; 17-274130, 17-274135, Exp. 9/13/2023.

Recall Number: D-1074-2023

Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Initiated
07-17-2023
Reported
08-09-2023
Quantity
9,517 syringes

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
92752
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Central Admixture Pharmacy Services Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
03-21-2025
Product Description About Product Description
Full technical description of the product.
lidocaine 2%, 100 mg /5 mL, (20 mg/mL), 5 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6006-1

Batch or Lot Expiration Information

Lot# Lot: 17-271076, Exp. 7/24/2023; 17-271132, 17-271165, Exp. 7/25/2023; 17-271230, 17-271250, Exp. 7/26/2023; 17-271508, Exp. 7/31/2023; 17-271595, 17-271604, Exp. 8/1/2023; 17-271658, Exp. 8/2/2023; 17-271764, Exp. 8/3/2023; 17-271826, Exp. 8/6/2023; 17-271972, Exp. 8/8/2023; 17-272052, 17-272057, Exp. 8/9/2023; 17-272139, Exp. 8/10/2023; 17-272258, Exp. 8/14/2023; 17-272470, Exp. 8/16/2023; 17-272690, Exp. 8/20/2023; 17-272822, Exp. 8/23/2023; 17-273054, 17-273065, Exp. 8/28/2023; 17-273423, Exp. 9/2/2023; 17-273771, Exp. 9/7/2023.